Related Experiment Video
Updated: Apr 16, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
The gouty tophus: a review
Ashika Chhana1, Nicola Dalbeth
1Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd. Grafton, Auckland, New Zealand, a.chhana@auckland.ac.nz.
Tophaceous gout involves monosodium urate (MSU) crystal deposits causing inflammation and joint damage. Effective treatment focuses on long-term urate-lowering therapy for tophi regression and improved quality of life.
Area of Science:
- Rheumatology
- Immunology
- Crystal Arthropathies
Background:
- Tophaceous gout is a hallmark of advanced gout, characterized by monosodium urate (MSU) crystal deposition.
- Tophi are chronic inflammatory structures impacting quality of life and leading to joint damage and increased mortality.
- Neutrophil interactions with MSU crystals may drive extracellular trap formation, a key process in tophus development.
Purpose of the Study:
- To review recent research on the biology, impact, and treatment of tophaceous gout.
- To highlight the role of MSU crystals and inflammatory responses in tophus formation.
- To discuss the implications of tophi on patient health and the effectiveness of current therapies.
Main Methods:
- Literature review of recent research on tophaceous gout.
- Microscopic analysis of tophus structure and composition.
- Examination of the impact of tophi on health-related quality of life and clinical outcomes.
Main Results:
- Tophi are granuloma-like structures containing MSU crystals, inflammatory cells, and connective tissue.
- Neutrophil extracellular trap formation is implicated as a critical step in tophus pathogenesis.
- Tophaceous gout significantly affects quality of life, joint integrity, and mortality risk.
Conclusions:
- Effective management of tophaceous gout necessitates long-term urate-lowering therapy to achieve serum urate levels below 5 mg/dL.
- Advances in gout therapeutics offer improved options for tophus regression and enhanced patient outcomes.
- Targeting urate levels is crucial for mitigating the detrimental effects of tophi in gout patients.
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi III: Medical Management
Nephrotic Syndrome II : Assessment and Medical Management
Tonsillitis II: Management
Acute Pyelonephritis I: Introduction
